Mass Spectrometry for Diabetic Nephropathy Monitoring: New Effective Tools for Physicians
Figure 4
MALDI-TOF analysis of urinary-digested 2D electrophoretic protein spots from nephrotic syndrome patients (protein spots were visualized by Coomassie staining and labelled NS1 to NS8). (a) Protein spots, corresponding to NS4, were subjected to in-gel digestion with trypsin. On the left panel, tryptic peptide masses were obtained by MALDI-TOF analysis; on the right panel, comparison of experimentally determined peptide masses of NS4 with theoretical peptide masses of α-1-antitrypsin. (b) MALDI-TOF profiles of tryptic peptides from protein spots corresponding to NS5 (Left panel) were obtained by MALDI-TOF analysis: comparison of experimentally determined peptide masses of RF2 with theoretical peptide masses of Zn-α-2-glycoprotein (Right panel). (c) MALDI-TOF profiles of tryptic peptides from protein spots corresponding to NS8 (Left panel) were obtained by MALDI-TOF analysis: comparison of experimentally determined peptide masses of NS8 with theoretical peptide masses of α-1-acid glycoprotein 2 (Right panel). Background peaks are marked with ‘*’ in the MALDI-TOF spectra [30].
